Dentsply Sirona (XRAY)
Market Price (12/30/2025): $11.22 | Market Cap: $2.2 BilSector: Health Care | Industry: Health Care Supplies
Dentsply Sirona (XRAY)
Market Price (12/30/2025): $11.22Market Cap: $2.2 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28% | Weak multi-year price returns2Y Excs Rtn is -111%, 3Y Excs Rtn is -139% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 94% |
| Attractive yieldDividend Yield is 4.3% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.1%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.5%, Rev Chg QQuarterly Revenue Change % is -4.9% | |
| Low stock price volatilityVol 12M is 43% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -39% | |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Aging Population & Chronic Disease, and Precision Medicine. Themes include AI in Healthcare Management, Show more. | Key risksXRAY key risks include [1] weakened demand and significant competitive pressure in its U.S. Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28% |
| Attractive yieldDividend Yield is 4.3% |
| Low stock price volatilityVol 12M is 43% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Aging Population & Chronic Disease, and Precision Medicine. Themes include AI in Healthcare Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -111%, 3Y Excs Rtn is -139% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 94% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.1%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.5%, Rev Chg QQuarterly Revenue Change % is -4.9% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -39% |
| Key risksXRAY key risks include [1] weakened demand and significant competitive pressure in its U.S. Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Dentsply Sirona reported a Q3 2025 adjusted EPS of $0.37, which missed the consensus estimate of $0.45, although it surpassed a lower analyst estimate of $0.18. This indicated ongoing operational challenges, despite strategic adjustments.
2. The company's Q3 2025 net sales decreased by 5.0% as-reported to $904 million compared to Q3 2024, and by 8.0% in constant currency. This decline was attributed in part to the Q3 2024 Byte impact and ERP pre-buy.
Stock Movement Drivers
Fundamental Drivers
The -9.5% change in XRAY stock from 9/29/2025 to 12/29/2025 was primarily driven by a -8.2% change in the company's P/S Multiple.| 9292025 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 12.43 | 11.25 | -9.49% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3671.00 | 3624.00 | -1.28% |
| P/S Multiple | 0.67 | 0.62 | -8.23% |
| Shares Outstanding (Mil) | 199.30 | 199.50 | -0.10% |
| Cumulative Contribution | -9.49% |
Market Drivers
9/29/2025 to 12/29/2025| Return | Correlation | |
|---|---|---|
| XRAY | -9.5% | |
| Market (SPY) | 3.6% | 42.4% |
| Sector (XLV) | 14.7% | 37.9% |
Fundamental Drivers
The -27.2% change in XRAY stock from 6/30/2025 to 12/29/2025 was primarily driven by a -25.1% change in the company's P/S Multiple.| 6302025 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 15.45 | 11.25 | -27.19% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3719.00 | 3624.00 | -2.55% |
| P/S Multiple | 0.83 | 0.62 | -25.13% |
| Shares Outstanding (Mil) | 199.10 | 199.50 | -0.20% |
| Cumulative Contribution | -27.19% |
Market Drivers
6/30/2025 to 12/29/2025| Return | Correlation | |
|---|---|---|
| XRAY | -27.2% | |
| Market (SPY) | 11.6% | 40.5% |
| Sector (XLV) | 16.1% | 50.9% |
Fundamental Drivers
The -37.7% change in XRAY stock from 12/29/2024 to 12/29/2025 was primarily driven by a -33.5% change in the company's P/S Multiple.| 12292024 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 18.06 | 11.25 | -37.70% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3900.00 | 3624.00 | -7.08% |
| P/S Multiple | 0.93 | 0.62 | -33.45% |
| Shares Outstanding (Mil) | 201.00 | 199.50 | 0.75% |
| Cumulative Contribution | -37.70% |
Market Drivers
12/29/2024 to 12/29/2025| Return | Correlation | |
|---|---|---|
| XRAY | -37.7% | |
| Market (SPY) | 16.6% | 49.5% |
| Sector (XLV) | 13.6% | 45.1% |
Fundamental Drivers
The -61.4% change in XRAY stock from 12/30/2022 to 12/29/2025 was primarily driven by a -60.0% change in the company's P/S Multiple.| 12302022 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 29.14 | 11.25 | -61.39% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 4042.00 | 3624.00 | -10.34% |
| P/S Multiple | 1.55 | 0.62 | -60.02% |
| Shares Outstanding (Mil) | 214.90 | 199.50 | 7.17% |
| Cumulative Contribution | -61.59% |
Market Drivers
12/30/2023 to 12/29/2025| Return | Correlation | |
|---|---|---|
| XRAY | -66.0% | |
| Market (SPY) | 47.9% | 37.7% |
| Sector (XLV) | 17.6% | 36.2% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| XRAY Return | -7% | 7% | -42% | 14% | -45% | -36% | -77% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 151% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 114% |
Monthly Win Rates [3] | |||||||
| XRAY Win Rate | 58% | 42% | 33% | 67% | 25% | 33% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| XRAY Max Drawdown | -44% | -7% | -51% | -13% | -51% | -46% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See XRAY Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/29/2025 (YTD)
How Low Can It Go
| Event | XRAY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -61.2% | -25.4% |
| % Gain to Breakeven | 157.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -47.5% | -33.9% |
| % Gain to Breakeven | 90.3% | 51.3% |
| Time to Breakeven | 350 days | 148 days |
| 2018 Correction | ||
| % Loss | -50.0% | -19.8% |
| % Gain to Breakeven | 99.8% | 24.7% |
| Time to Breakeven | 918 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -53.1% | -56.8% |
| % Gain to Breakeven | 113.2% | 131.3% |
| Time to Breakeven | 1,696 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Dentsply Sirona's stock fell -61.2% during the 2022 Inflation Shock from a high on 5/10/2021. A -61.2% loss requires a 157.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces. The company also provides dental CAD/CAM products, digital impressions intraoral scanners, mills, and services; and orthodontic products, including high frequency vibration technology device under the name VPro, dentist-directed clear aligner solutions under the name SureSmile, and direct-to-consumer clear aligner solutions under the name Byte; dental implant products, bone regenerative and restorative solutions, and educational programs; and urology catheters and other healthcare-related consumable products. In addition, it offers endodontic products comprising endodontic instruments and materials, drills, filers, sealers, irrigation needles, and other tools or single-use solutions; restorative products that include dental prosthetics, such as artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products; small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers; and dental supplies, including dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.
AI Analysis | Feedback
Here are 1-3 brief analogies for Dentsply Sirona:
- GE Healthcare for dentistry
- Stryker for dental professionals
- The Apple of dental technology
AI Analysis | Feedback
- Digital Imaging Systems: Provides X-ray machines, intraoral cameras, and 3D cone beam computed tomography (CBCT) systems for comprehensive dental diagnostics and treatment planning.
- CAD/CAM Systems: Offers integrated hardware and software solutions, such as CEREC, enabling dentists to design, mill, and place dental restorations like crowns and veneers in a single visit.
- Treatment Centers & Instruments: Manufactures dental chairs, integrated delivery systems, and a wide array of handheld instruments essential for various dental procedures.
- Restorative Materials: Supplies a broad range of composites, bonding agents, ceramics, and other materials used for direct and indirect dental fillings, crowns, and bridges.
- Dental Implants: Delivers complete systems for tooth replacement, encompassing implants, abutments, and surgical kits for effective osseointegration.
- Endodontic Products: Provides specialized instruments and materials, including files, sealers, and obturators, vital for successful root canal treatments.
- Orthodontic Solutions: Offers clear aligner systems (SureSmile), traditional brackets, wires, and other products designed for effective tooth alignment and bite correction.
- Preventive & Prophylaxis Products: Produces professional dental cleaning tools, fluoride treatments, and sealants aimed at promoting long-term oral health and preventing dental issues.
AI Analysis | Feedback
Dentsply Sirona (symbol: XRAY) primarily sells its products and solutions to other companies and organizations within the dental industry, rather than directly to individuals. Their major customers can be categorized as follows:- Dental Distributors: These companies purchase Dentsply Sirona's products in bulk and then resell them to individual dental practices, laboratories, and specialists globally. Major public company customers in this category include:
- Henry Schein, Inc. (symbol: HSIC)
- Patterson Companies Inc. (symbol: PDCO)
- Dental Service Organizations (DSOs): These are management companies that own or manage groups of dental practices. DSOs often centralize their purchasing decisions, making them significant customers for dental suppliers like Dentsply Sirona. Many DSOs are privately held.
- Institutional Buyers: This category includes dental schools, universities, hospitals, and government health agencies that equip their facilities with dental technology, equipment, and consumables.
AI Analysis | Feedback
null
AI Analysis | Feedback
Daniel Scavilla, President and Chief Executive Officer
Daniel Scavilla was appointed President and Chief Executive Officer of Dentsply Sirona, effective August 1, 2025. He brings over three decades of experience in the medical technology and pharmaceutical industries. Prior to joining Dentsply Sirona, Mr. Scavilla served as President and CEO of Globus Medical, where he oversaw the acquisition of NuVasive and the subsequent integration of the two organizations, forming the world's second-largest spine technology company. His roles at Globus Medical also included Chief Financial Officer, Executive Vice President, Chief Commercial Officer, and President of Trauma, during which he expanded manufacturing and distribution operations and launched the orthopedics and trauma division. Before Globus Medical, he spent 28 years in various financial and operational leadership positions at Johnson & Johnson.
Matthew E. Garth, Executive Vice President and Chief Financial Officer
Matthew E. Garth was named Executive Vice President and Chief Financial Officer for Dentsply Sirona, effective May 30, 2025. He possesses nearly 30 years of experience in financial leadership and strategic transformation across several multinational corporations. Before joining Dentsply Sirona, Mr. Garth was the Chief Financial Officer and Chief Administrative Officer at The Scotts Miracle-Gro Company, where he contributed to stabilizing the business after the pandemic and developing long-term strategic plans. His career also includes senior financial leadership roles at Minerals Technologies Inc., where he held global responsibility for finance, tax, treasury, audit, investor relations, information technology, and shared services, and at Alcoa Corp., where he served as CFO for two multi-billion-dollar business units. Mr. Garth began his career at Thomson Financial. He holds a Bachelor of Science in Accounting from the University of Delaware and an MBA from Columbia University.
Andreas Frank, Executive Vice President, Chief Business Officer
Andreas Frank serves as Executive Vice President, Chief Business Officer at Dentsply Sirona. No detailed background is available in the provided search results.
Andrea Frohning, Senior Vice President & Chief Human Resources Officer
Andrea Frohning is the Senior Vice President & Chief Human Resources Officer at Dentsply Sirona. No detailed background is available in the provided search results.
Kevin Boyle, Senior Vice President & Chief Technology Officer
Kevin Boyle holds the position of Senior Vice President & Chief Technology Officer at Dentsply Sirona. No detailed background is available in the provided search results.
AI Analysis | Feedback
Dentsply Sirona (XRAY) faces several key risks to its business operations:- Weakened Demand, Competitive Pressures, and Operational Underperformance in Key Markets: The company has experienced weakened demand and significant competitive pressures, particularly in its U.S. implants business and equipment sales, leading to substantial non-cash impairment charges for goodwill and other intangible assets in 2024. This underperformance in critical markets, especially the U.S., is a major focus for management's "Return-to-Growth" action plan.
- Cybersecurity Incidents: Dentsply Sirona relies heavily on information and technology for its operations and product portfolios. Any cyber incidents could significantly harm its operations, lead to intellectual property theft, expose it to fraud or extortion, result in harm to employees or customers, cause violations of privacy laws or other regulatory and compliance lapses, damage its reputation, and impact its ability to consistently deliver digital business solutions.
- Regulatory and Compliance Risks: As a manufacturer of professional dental products and technologies, the majority of Dentsply Sirona's products are classified as medical devices. This subjects the company to extensive restrictions under domestic and foreign laws, rules, regulations, and self-regulatory codes, including but not limited to the U.S. Food, Drug, and Cosmetic Act and the EU's Medical Devices Directive. Non-compliance with these regulations could lead to penalties and impact business operations.
AI Analysis | Feedback
nullAI Analysis | Feedback
Dentsply Sirona operates in several significant addressable markets within the dental industry. The estimated market sizes for their main products and services globally are as follows:
- Dental Equipment: The global dental equipment market was valued at approximately USD 11.95 billion in 2024 and is projected to reach around USD 22.1 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 6.34% from 2025 to 2034. North America held the largest share of the dental equipment market in 2023.
- Dental Consumables: The global dental consumables market size was estimated at USD 36.37 billion in 2024 and is projected to reach USD 73.46 billion by 2033, growing at a CAGR of 8.17% from 2025 to 2033. North America dominated the global industry with the largest revenue share of 47.54% in 2024.
- Dental Implants: The global dental implants market size was valued at USD 6.8 billion in 2024 and is estimated to reach USD 9.8 billion by 2033, demonstrating a CAGR of 4.16% from 2025 to 2033. North America currently dominates this market, holding a share of over 36.8% in 2024.
- Clear Aligners: The global clear aligners market size is calculated at USD 6.51 billion in 2024 and is projected to reach approximately USD 99.44 billion by 2034, expanding at a CAGR of 31.34% between 2025 and 2034. North America dominated the global clear aligners market in 2024.
- Dental CAD/CAM Systems: The global dental CAD/CAM market size was valued at USD 2.81 billion in 2024 and is predicted to increase from USD 3.10 billion in 2025 to approximately USD 7.48 billion by 2034, expanding at a CAGR of 10.29% from 2025 to 2034. North America led the market with the biggest market share in 2024.
- Dental Imaging Systems: The global dental imaging market size was valued at USD 4.79 billion in 2024 and is expected to hit USD 11.62 billion by 2034, growing at a CAGR of 9.27% from 2025 to 2034. North America dominated the dental imaging market in 2024.
AI Analysis | Feedback
Dentsply Sirona (XRAY) is focusing on several key initiatives to drive future revenue growth over the next two to three years, primarily encapsulated in its "Return to Growth" action plan. This comprehensive strategy aims for sustained profitable growth.
The expected drivers of future revenue growth include:
- Enhanced Innovation through Increased R&D and New Product Launches: Dentsply Sirona is making targeted investments in research and development, pulling forward R&D investments to strengthen its position for 2026 and beyond, with a goal to reach 6% to 7% R&D investment. This focus on innovation is intended to accelerate growth momentum, launch new products, and add value to clinicians' workflows. The company also aims to shape the future of its markets by migrating from product offerings to proceduralization, leveraging its broad portfolio.
- Strategic Focus on the U.S. Market and Customer Experience: A significant part of the "Return to Growth" plan involves reigniting growth in the U.S. market, which has experienced sales declines. The company plans to restructure commercial operations, particularly in the U.S., and enhance customer engagement and experience to address these challenges.
- Growth of Key Product Segments, particularly Wellspect and SureSmile: The Wellspect Healthcare business has shown strong performance, with significant growth in both the U.S. and Europe, and is expected to continue driving growth. Similarly, the SureSmile clear aligner segment is anticipated to contribute to growth, with notable expansion in regions like Europe and market share gains in clear aligners.
- Operational Efficiency and Organizational Strengthening: Dentsply Sirona is focusing on streamlining operations, strengthening its organizational foundation, and enhancing its enterprise AI and automation strategy. These initiatives are aimed at improving overall performance, freeing up capital for growth initiatives, and contributing to sustainable and profitable growth.
AI Analysis | Feedback
Share Repurchases
- In November 2023, Dentsply Sirona's Board of Directors approved a $1.0 billion increase to its authorized share repurchase program.
- As of December 31, 2024, the company had $1.2 billion remaining under this share repurchase authorization.
- For the year ended December 31, 2024, Dentsply Sirona repurchased approximately 9.4 million shares at a cost of $250 million.
Outbound Investments
- In fiscal year 2020, Dentsply Sirona made cash acquisitions totaling $1,078 million.
- The company made cash acquisitions of $248 million in fiscal year 2021.
Capital Expenditures
- Dentsply Sirona estimates capital expenditures for the full year 2025 to be in the range of approximately $130 million to $140 million.
- These investments are primarily focused on the ongoing implementation of a new global ERP system, equipment upgrades, and capacity expansion to support product innovation and consolidate operations.
- Historical capital expenditures were approximately $180 million in fiscal year 2024, $149 million in fiscal year 2023, and $149 million in fiscal year 2022.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to XRAY. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.4% | -9.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 17.0% | 17.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.1% | 3.1% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
| 04302022 | XRAY | Dentsply Sirona | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -22.2% | 6.5% | -32.4% |
| 03312020 | XRAY | Dentsply Sirona | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.6% | 65.7% | -8.7% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Dentsply Sirona
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.06 |
| Mkt Cap | 159.0 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 2.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 159.0 |
| P/S | 2.7 |
| P/EBIT | 21.1 |
| P/E | 33.0 |
| P/CFO | 16.1 |
| Total Yield | 3.9% |
| Dividend Yield | 2.1% |
| FCF Yield 3Y Avg | 5.7% |
| D/E | 0.4 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.1% |
| 3M Rtn | 4.5% |
| 6M Rtn | 9.2% |
| 12M Rtn | 11.5% |
| 3Y Rtn | 72.0% |
| 1M Excs Rtn | -0.4% |
| 3M Excs Rtn | 0.9% |
| 6M Excs Rtn | -2.1% |
| 12M Excs Rtn | -4.0% |
| 3Y Excs Rtn | -5.1% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Essential Dental Solutions | 1,468 | 1,427 | |||
| Connected Technology Solutions | 1,169 | 1,219 | |||
| Orthodontic and Implant Solutions | 1,040 | 1,006 | |||
| Wellspect Healthcare | 288 | 270 | |||
| Consumables | 1,727 | 1,381 | 1,746 | ||
| Technologies & Equipment | 2,504 | 1,961 | 2,283 | ||
| Total | 3,965 | 3,922 | 4,231 | 3,342 | 4,029 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Essential Dental Solutions | 478 | 467 | |||
| Orthodontic and Implant Solutions | 156 | 193 | |||
| Connected Technology Solutions | 101 | 161 | |||
| Wellspect Healthcare | 87 | 73 | |||
| Depreciation resulting from the fair value step-up of property, plant, and equipment from business | -3 | -3 | -6 | -6 | -7 |
| Restructuring and other costs | -67 | -14 | -17 | -77 | -81 |
| Amortization of intangible assets | -211 | -209 | -222 | -192 | -189 |
| Goodwill and intangible asset impairments | -307 | -1,287 | |||
| Unallocated corporate costs | -319 | ||||
| All Other | -318 | -229 | -281 | -269 | |
| Consumables | 539 | 314 | 440 | ||
| Goodwill Impairment | 0 | -157 | 0 | ||
| Intangible asset impairments | 0 | ||||
| Technologies & Equipment | 543 | 387 | 467 | ||
| Total | -85 | -937 | 608 | -12 | 361 |
Price Behavior
Price Behavior
| Market Price | $11.25 | |
| Market Cap ($ Bil) | 2.2 | |
| First Trading Date | 04/25/1991 | |
| Distance from 52W High | -41.9% | |
| 50 Days | 200 Days | |
| DMA Price | $11.40 | $13.47 |
| DMA Trend | down | down |
| Distance from DMA | -1.3% | -16.5% |
| 3M | 1YR | |
| Volatility | 41.1% | 42.8% |
| Downside Capture | 169.98 | 172.73 |
| Upside Capture | 92.03 | 100.09 |
| Correlation (SPY) | 42.0% | 49.4% |
XRAY Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.70 | 1.49 | 1.62 | 1.60 | 1.08 | 0.97 |
| Up Beta | 1.33 | 1.80 | 2.31 | 1.70 | 0.94 | 0.97 |
| Down Beta | -2.00 | 1.16 | 1.13 | 1.31 | 0.85 | 0.90 |
| Up Capture | 143% | 97% | 75% | 86% | 100% | 41% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 9 | 20 | 30 | 59 | 120 | 377 |
| Down Capture | 275% | 189% | 219% | 215% | 134% | 106% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 11 | 22 | 33 | 66 | 127 | 365 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of XRAY With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| XRAY | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -37.2% | 13.8% | 16.7% | 65.4% | 7.5% | 4.2% | -7.3% |
| Annualized Volatility | 42.6% | 17.2% | 19.4% | 19.8% | 15.3% | 17.0% | 34.9% |
| Sharpe Ratio | -0.98 | 0.59 | 0.67 | 2.43 | 0.27 | 0.08 | -0.06 |
| Correlation With Other Assets | 45.1% | 49.4% | -2.1% | 12.7% | 46.1% | 30.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of XRAY With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| XRAY | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -24.9% | 8.4% | 14.8% | 17.7% | 11.2% | 5.1% | 30.2% |
| Annualized Volatility | 35.5% | 14.5% | 17.1% | 15.6% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | -0.71 | 0.40 | 0.70 | 0.91 | 0.48 | 0.18 | 0.57 |
| Correlation With Other Assets | 39.2% | 42.9% | 7.7% | 10.6% | 40.5% | 17.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of XRAY With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| XRAY | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -14.1% | 10.1% | 15.0% | 14.6% | 6.9% | 5.4% | 69.0% |
| Annualized Volatility | 33.3% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | -0.37 | 0.50 | 0.72 | 0.82 | 0.31 | 0.23 | 0.89 |
| Correlation With Other Assets | 45.0% | 47.4% | 2.3% | 15.8% | 44.3% | 13.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | -12.7% | -14.1% | -12.0% |
| 7/21/2025 | -0.3% | 2.2% | -11.6% |
| 5/8/2025 | 16.3% | 20.2% | 16.5% |
| 2/27/2025 | -8.8% | -14.1% | -16.9% |
| 10/24/2024 | -4.5% | -5.1% | -23.1% |
| 7/31/2024 | 1.3% | -9.8% | -7.7% |
| 2/29/2024 | -1.9% | 0.3% | 0.2% |
| 11/2/2023 | -7.5% | -10.2% | 5.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 7 | 7 |
| # Negative | 14 | 14 | 14 |
| Median Positive | 2.6% | 3.6% | 9.9% |
| Median Negative | -7.2% | -8.7% | -11.5% |
| Max Positive | 16.3% | 20.2% | 17.1% |
| Max Negative | -12.7% | -14.1% | -23.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/07/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/08/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 02/27/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/07/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 07/31/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/02/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 02/29/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/02/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/07/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/03/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/01/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/14/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 11/07/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 11/07/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/01/2022 | 10-K (12/31/2021) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.